Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Jonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, Gil Yosipovitch, Sonja Ständer, Hernan Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E Myers, Claire Feeney, Marco DiBonaventura

Abstrakt

Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children’s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children’s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age.

OriginalsprogEngelsk
Publikationsdatosep. 2021
Udgave5
Vol/bind22
Antal sider1
DOI
StatusUdgivet - sep. 2021
NavnAmerican Journal of Clinical Dermatology
ISSN1175-0561

Fingeraftryk

Dyk ned i forskningsemnerne om 'Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes'. Sammen danner de et unikt fingeraftryk.

Citationsformater